This article highlights the results from the Ticagrelor in CABG (TiCAB) trial, which examined the use of Ticagrelor monotherapy in coronary artery bypass grafting (CABG) compared to aspirin. This study involved 752 patients. The authors found no significant difference in major adverse cardiac and cerebrovascular events (MACCE) between the aspirin and Ticagrelor groups, even when stratified for different complexity levels of coronary disease based on SYNTAX scores.